Publikationen in Zusammenarbeit mit Forschern von Medical University of Vienna (17)

2023

  1. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

    Annals of Oncology

  2. Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours

    Nature Reviews Clinical Oncology, Vol. 20, Núm. 6, pp. 372-389

2022

  1. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer

    Cancer Treatment Reviews, Vol. 111

2021

  1. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

    Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581

  2. Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer

    Cancers, Vol. 13, Núm. 17

  3. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer ☆

    Annals of Oncology, Vol. 32, Núm. 12, pp. 1475-1495

  4. Expected medium- And long-term impact of the COVID-19 outbreak in oncology

    JCO Global Oncology, Vol. 7, pp. 162-172

  5. Human Microbiota and Breast Cancer—Is There Any Relevant Link?—A Literature Review and New Horizons Toward Personalised Medicine

    Frontiers in Microbiology, Vol. 12

  6. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. ASCO 2020

    Breast Care

  2. ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer

    ESMO Open, Vol. 5

  3. Oncological care organisation during COVID-19 outbreak

    ESMO Open, Vol. 5, Núm. 4

2019

  1. Breast cancer

    Nature Reviews Disease Primers, Vol. 5, Núm. 1

2016

  1. Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel

    Annals of Oncology, Vol. 27, Núm. 3, pp. 379-390

  2. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

    Annals of Oncology, Vol. 27, Núm. 11, pp. 2046-2052

2011

  1. Corrigendum to " Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine" [Vaccine 28 (2010) 8065-8072]

    Vaccine

2010

  1. Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine

    Vaccine, Vol. 28, Núm. 51, pp. 8065-8072